MAP1LC3C / LC3C (C-Terminus) IHC-plus Antibody from MYBIOSOURCE INC.

Search, find, compare suppliers for anti-MAP1LC3C / LC3C (C-Terminus) IHC-plus antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityMAP1LC3C / LC3C (C-Terminus) IHC-plus
Clonepolyclonal
Host SpeciesRabbit
Reactive Specieshuman
Isotypen/a
Formatimmunoaffinity purified
Size0.05 mg
Concentration1 mg/ml
ApplicationsImmunohistochemistry (IHC) Paraffin, Immunofluorescence (IF), Western Blot (WB), ELISA (EIA)
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionSpecificity: MAP1LC3C antibody is human, mouse and rat reactive. Multiple isoforms MAP1LC3C are known to exist. MAP1LC3C antibody is predicted to not cross-react with MAP1LC3A or MAP1LC3B. MAP1LC3C Antibody, ATG8J Antibody, LC3C Antibody, MAP1A/MAP1B LC3 C Antibody, MAP1A/MAP1B light chain 3 C Antibody, LC3-like protein 2 Antibody Description: Ubiquitin-like modifier that plays a crucial role in antibacterial autophagy (xenophagy) through the selective binding of CALCOCO2. Recruites all ATG8 family members to infecting bacteria such as S.Typhimurium.
ImmunogenImmunogen Description: 18 amino acid peptide near the carboxy terminus of human MAP1LC3C.
Other Names[Rabbit (IgG) to Human MAP1LC3C / LC3C; Human MAP1LC3C / LC3C; ATG8J; MAP1A/MAP1B LC3 C; MAP1A/MAP1B light chain 3 C; LC3-like protein 2], [MAP1LC3C; MAP1LC3C; LC3C; ATG8J; MAP1A/MAP1B LC3 C]
Gene, Accession #[MAP1LC3C / LC3C], Gene ID: 440738, NCBI: NP_001004343.1, UniProt: Q9BXW4
Catalog #MBS249990
Price$660
Order / More InfoMAP1LC3C / LC3C (C-Terminus) IHC-plus Antibody from MYBIOSOURCE INC.
Product Specific Referencesn/a
MYBIOSOURCE INC.
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166

sales@mybiosource.com

http://www.MyBioSource.com

Profile of MYBIOSOURCE INC.
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.